Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

24-hour BREO delivers improved symptom control.
All day and night.

Based on a 12-week study of patients who remained symptomatic* on a mid- to high-dose ICS, BREO provided:

FF=fluticasone furoate; ICS=inhaled corticosteroid.

FF=fluticasone furoate; ICS=inhaled corticosteroid.

24-hour BREO delivers improved symptom control.
All day and night.

In a 24-week study of patients who were symptomatic on a mid- to high-dose ICS,
BREO provided:

FF=fluticasone furoate; ICS=inhaled corticosteroid.

FF=fluticasone furoate; ICS=inhaled corticosteroid.

Looking for samples?
Looking for a savings offer?

Subject to eligibility. Restrictions apply.

REFERENCES:

  1. Bernstein DI, Bateman ED, Woodcock A, et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma. 2018;55(8):890-897.
  2. Bleecker ER, Lötvall J, O’Byrne PM, et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014;2(5):553-561.
  3. Bateman ED, O’Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014;69(4):312-319.
  4. Data on file, GSK.
  5. O’Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014;43:773-782.
  6. Kerwin E, Barnes N, Gibbs M, et al. Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms; post-hoc analyses of three randomized controlled trials. J Asthma. 2018;55(8):890-897.
  7. Data on file, GSK. Study 201594.